{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:04:18Z","timestamp":1787504658306,"version":"build-2736575974"},"reference-count":67,"publisher":"Elsevier BV","issue":"42","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Medigene AG","award":["P50 CA098252"],"award-info":[{"award-number":["P50 CA098252"]}]},{"name":"Public Health Service","award":["CA118790"],"award-info":[{"award-number":["CA118790"]}]},{"name":"Medigene AG"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.vaccine.2015.09.005","type":"journal-article","created":{"date-parts":[[2015,9,15]],"date-time":"2015-09-15T04:12:15Z","timestamp":1442290335000},"page":"5553-5563","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Durable immunity to oncogenic human papillomaviruses elicited by adjuvanted recombinant Adeno-associated virus-like particle immunogen displaying L2 17\u201336 epitopes"],"prefix":"10.1016","volume":"33","author":[{"given":"Subhashini","family":"Jagu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balusubramanyam","family":"Karanam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua W.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatem","family":"Zayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margit","family":"Weghofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah A.","family":"Brendle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karla K.","family":"Balogh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin Pino","family":"Tossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard B.S.","family":"Roden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil D.","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.vaccine.2015.09.005_bib0340","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.tim.2010.11.004","article-title":"Papillomaviruses: evolution Linnaean taxonomy and current nomenclature","volume":"19","author":"Van","year":"2011","journal-title":"Trends Microbiol"},{"issue":"3","key":"10.1016\/j.vaccine.2015.09.005_bib0345","first-page":"209","article-title":"Human papillomavirus & cervical cancer","volume":"130","author":"Zur Hausen","year":"2009","journal-title":"Indian J Med Res"},{"issue":"1","key":"10.1016\/j.vaccine.2015.09.005_bib0350","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/sj.bjc.6600688","article-title":"Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis","volume":"88","author":"Clifford","year":"2003","journal-title":"Br J Cancer"},{"issue":"Aug (2)","key":"10.1016\/j.vaccine.2015.09.005_bib0355","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/ijc.20244","article-title":"Against which human papillomavirus types shall we vaccinate and screen?, The international perspective","volume":"111","author":"Munoz","year":"2004","journal-title":"Int J Cancer"},{"issue":"Feb (6)","key":"10.1016\/j.vaccine.2015.09.005_bib0360","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa021641","article-title":"Epidemiologic classification of human papillomavirus types associated with cervical cancer","volume":"348","author":"Munoz","year":"2003","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.vaccine.2015.09.005_bib0365","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1158\/1055-9965.EPI-14-0410","article-title":"Attribution of 12 high-risk human papillomavirus genotypes to infection and cervical disease","volume":"23","author":"Joura","year":"2014","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"Dec (Suppl 7)","key":"10.1016\/j.vaccine.2015.09.005_bib0370","doi-asserted-by":"crossref","first-page":"H1","DOI":"10.1016\/j.vaccine.2013.10.003","article-title":"Comprehensive control of human papillomavirus infections and related diseases","volume":"31","author":"Bosch","year":"2013","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2015.09.005_bib0375","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1158\/1055-9965.EPI-14-0580","article-title":"Prevalence of human papillomavirus in cancer of the oropharynx by gender","volume":"23","author":"Combes","year":"2014","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"May (1)","key":"10.1016\/j.vaccine.2015.09.005_bib0380","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.virol.2010.02.002","article-title":"Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments","volume":"401","author":"Bernard","year":"2010","journal-title":"Virology"},{"issue":"Nov (16)","key":"10.1016\/j.vaccine.2015.09.005_bib0385","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1016\/j.ejca.2014.07.018","article-title":"Large contribution of human papillomavirus in vaginal neoplastic lesions: a worldwide study in 597 samples","volume":"50","author":"Alemany","year":"2014","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.vaccine.2015.09.005_bib0390","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/ijc.28963","article-title":"Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide","volume":"136","author":"Alemany","year":"2015","journal-title":"Int J Cancer"},{"issue":"Mar","key":"10.1016\/j.vaccine.2015.09.005_bib0395","first-page":"98","article-title":"Prevalence of HPV infection in head and neck carcinomas shows geographical variability: a comparative study from Brazil and Germany","author":"Hauck","year":"2015","journal-title":"Virchows Arch"},{"key":"10.1016\/j.vaccine.2015.09.005_bib0400","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/978-1-4939-1804-1_20","article-title":"Human papilloma virus (HPV) modulation of the HNSCC epigenome","volume":"1238","author":"Stephen","year":"2015","journal-title":"Methods Mol Biol"},{"issue":"Nov (22)","key":"10.1016\/j.vaccine.2015.09.005_bib0405","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1093\/jnci\/djs395","article-title":"Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: a model-based analysis","volume":"104","author":"Van d","year":"2012","journal-title":"J Natl Cancer Inst"},{"issue":"10","key":"10.1016\/j.vaccine.2015.09.005_bib0410","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1473-3099(12)70187-1","article-title":"Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis","volume":"12","author":"Malagon","year":"2012","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2015.09.005_bib0415","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1586\/erv.12.151","article-title":"Virus-like particles for the prevention of human papillomavirus-associated malignancies","volume":"12","author":"Wang","year":"2013","journal-title":"Expert Rev Vaccines"},{"issue":"Nov (21)","key":"10.1016\/j.vaccine.2015.09.005_bib0420","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1056\/NEJMoa020586","article-title":"A controlled trial of a human papillomavirus type 16 vaccine","volume":"347","author":"Koutsky","year":"2002","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.vaccine.2015.09.005_bib0425","doi-asserted-by":"crossref","first-page":"e83431","DOI":"10.1371\/journal.pone.0083431","article-title":"Long-term follow-up observation of the safety, immunogenicity, and effectiveness of Gardasil in adult women","volume":"8","author":"Luna","year":"2013","journal-title":"PLoS ONE"},{"issue":"12","key":"10.1016\/j.vaccine.2015.09.005_bib0430","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.4161\/hv.36121","article-title":"Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine and HPV-6\/11\/16\/18 vaccine in healthy women aged 18\u201345 years: end-of-study analysis of a Phase III randomized trial","volume":"10","author":"Einstein","year":"2014","journal-title":"Hum Vaccin Immunother"},{"issue":"Feb (8)","key":"10.1016\/j.vaccine.2015.09.005_bib0435","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1405044","article-title":"A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women","volume":"372","author":"Joura","year":"2015","journal-title":"N Engl J Med"},{"issue":"Apr (15)","key":"10.1016\/j.vaccine.2015.09.005_bib0440","doi-asserted-by":"crossref","first-page":"5850","DOI":"10.1073\/pnas.0800868105","article-title":"Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2","volume":"105","author":"Alphs","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"issue":"Dec (24)","key":"10.1016\/j.vaccine.2015.09.005_bib0445","doi-asserted-by":"crossref","first-page":"13927","DOI":"10.1128\/JVI.00936-07","article-title":"A protective and broadly cross-neutralizing epitope of human papillomavirus L2","volume":"81","author":"Gambhira","year":"2007","journal-title":"J Virol"},{"issue":"May (2)","key":"10.1016\/j.vaccine.2015.09.005_bib0450","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1006\/viro.2000.0272","article-title":"Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes","volume":"270","author":"Roden","year":"2000","journal-title":"Virology"},{"issue":"1","key":"10.1016\/j.vaccine.2015.09.005_bib0455","doi-asserted-by":"crossref","first-page":"43","DOI":"10.4161\/hv.5.1.6554","article-title":"Development of an HPV vaccine for a broad spectrum of high-risk types","volume":"5","author":"Kanda","year":"2009","journal-title":"Hum Vaccin"},{"issue":"7","key":"10.1016\/j.vaccine.2015.09.005_bib0460","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1089\/hum.2011.202","article-title":"Intranasal vaccination with AAV5 and 9 vectors against human papillomavirus type 16 in rhesus macaques","volume":"23","author":"Nieto","year":"2012","journal-title":"Hum Gene Ther"},{"issue":"6","key":"10.1016\/j.vaccine.2015.09.005_bib0465","doi-asserted-by":"crossref","first-page":"e39741","DOI":"10.1371\/journal.pone.0039741","article-title":"Development of AAVLP (HPV16\/31L2) particles as broadly protective HPV vaccine candidate","volume":"7","author":"Nieto","year":"2012","journal-title":"PLoS ONE"},{"issue":"Jan (2)","key":"10.1016\/j.vaccine.2015.09.005_bib0470","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1128\/JVI.78.2.751-757.2004","article-title":"Efficient intracellular assembly of papillomaviral vectors","volume":"78","author":"Buck","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2015.09.005_bib0475","first-page":"445","article-title":"Generation of HPV pseudovirions using transfection and their use in neutralization assays","volume":"119","author":"Buck","year":"2005","journal-title":"Methods Mol Med"},{"issue":"Dec (24)","key":"10.1016\/j.vaccine.2015.09.005_bib0480","doi-asserted-by":"crossref","first-page":"12393","DOI":"10.1128\/JVI.01583-06","article-title":"Preclinical model to test human papillomavirus virus (HPV) capsid vaccines in vivo using infectious HPV\/cottontail rabbit papillomavirus chimeric papillomavirus particles","volume":"80","author":"Mejia","year":"2006","journal-title":"J Virol"},{"issue":"Aug (2)","key":"10.1016\/j.vaccine.2015.09.005_bib0485","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0166-0934(03)00170-8","article-title":"Quantitative RT-PCR assay for HPV infection in cultured cells","volume":"111","author":"Culp","year":"2003","journal-title":"J Virol Methods"},{"issue":"Nov (22)","key":"10.1016\/j.vaccine.2015.09.005_bib0490","doi-asserted-by":"crossref","first-page":"11381","DOI":"10.1128\/JVI.01328-06","article-title":"Papillomavirus particles assembled in 293TT cells are infectious in vivo","volume":"80","author":"Culp","year":"2006","journal-title":"J Virol"},{"issue":"7","key":"10.1016\/j.vaccine.2015.09.005_bib0495","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/nm1598","article-title":"Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan","volume":"13","author":"Roberts","year":"2007","journal-title":"Nat Med"},{"issue":"Jun (28)","key":"10.1016\/j.vaccine.2015.09.005_bib0500","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1016\/j.vaccine.2014.04.032","article-title":"Low doses of flagellin-L2 multimer vaccines protect against challenge with diverse papillomavirus genotypes","volume":"32","author":"Kalnin","year":"2014","journal-title":"Vaccine"},{"issue":"Mar (1\u20132)","key":"10.1016\/j.vaccine.2015.09.005_bib0505","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jviromet.2007.10.005","article-title":"Wounding prior to challenge substantially improves infectivity of cottontail rabbit papillomavirus and allows for standardization of infection","volume":"148","author":"Cladel","year":"2008","journal-title":"J Virol Methods"},{"issue":"Jan","key":"10.1016\/j.vaccine.2015.09.005_bib0510","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.virol.2013.10.038","article-title":"Preparation and properties of a papillomavirus infectious intermediate and its utility for neutralization studies","volume":"449","author":"Wang","year":"2014","journal-title":"Virology"},{"issue":"2","key":"10.1016\/j.vaccine.2015.09.005_bib0515","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1158\/1940-6207.CAPR-14-0311","article-title":"Immunoprevention of human papillomavirus-associated malignancies","volume":"8","author":"Wang","year":"2015","journal-title":"Cancer Prev Res (Phila)"},{"issue":"5","key":"10.1016\/j.vaccine.2015.09.005_bib0520","doi-asserted-by":"crossref","first-page":"3298","DOI":"10.1128\/jvi.70.5.3298-3301.1996","article-title":"Assessment of the serological relatedness of genital human papillomaviruses by hemagglutination inhibition","volume":"70","author":"Roden","year":"1996","journal-title":"J Virol"},{"issue":"Feb (13\u201314)","key":"10.1016\/j.vaccine.2015.09.005_bib0525","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1016\/S0264-410X(00)00370-4","article-title":"Immunological analyses of human papillomavirus capsids","volume":"19","author":"Giroglou","year":"2001","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.vaccine.2015.09.005_bib0530","doi-asserted-by":"crossref","first-page":"e75677","DOI":"10.1371\/journal.pone.0075677","article-title":"High-throughput pseudovirion-based neutralization assay for analysis of natural and vaccine-induced antibodies against human papillomaviruses","volume":"8","author":"Sehr","year":"2013","journal-title":"PLoS ONE"},{"issue":"Dec (11)","key":"10.1016\/j.vaccine.2015.09.005_bib0535","doi-asserted-by":"crossref","first-page":"6120","DOI":"10.4049\/jimmunol.169.11.6120","article-title":"Determinants of autoantibody induction by conjugated papillomavirus virus-like particles","volume":"169","author":"Chackerian","year":"2002","journal-title":"J Immunol"},{"issue":"Oct (1\u20132)","key":"10.1016\/j.vaccine.2015.09.005_bib0540","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.virol.2013.04.017","article-title":"L2, the minor capsid protein of papillomavirus","volume":"445","author":"Wang","year":"2013","journal-title":"Virology"},{"issue":"12","key":"10.1016\/j.vaccine.2015.09.005_bib0545","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1038\/jid.2013.253","article-title":"Efficacy of RG1-VLP vaccination against infections with genital and cutaneous human papillomaviruses","volume":"133","author":"Schellenbacher","year":"2013","journal-title":"J Invest Dermatol"},{"issue":"Mar (11)","key":"10.1016\/j.vaccine.2015.09.005_bib0550","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1016\/j.vaccine.2006.11.049","article-title":"A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11","volume":"25","author":"Slupetzky","year":"2007","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2015.09.005_bib0555","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1002\/jmv.21124","article-title":"Modification of human papillomavirus-like particle vaccine by insertion of the cross-reactive L2-epitopes","volume":"80","author":"Kondo","year":"2008","journal-title":"J Med Virol"},{"issue":"Aug (15)","key":"10.1016\/j.vaccine.2015.09.005_bib0560","doi-asserted-by":"crossref","first-page":"8386","DOI":"10.1128\/JVI.77.15.8386-8393.2003","article-title":"Chimeric human papillomavirus type 16 (HPV-16) L1 particles presenting the common neutralizing epitope for the L2 minor capsid protein of HPV-6 and HPV-16","volume":"77","author":"Varsani","year":"2003","journal-title":"J Virol"},{"issue":"8","key":"10.1016\/j.vaccine.2015.09.005_bib0565","doi-asserted-by":"crossref","first-page":"e23310","DOI":"10.1371\/journal.pone.0023310","article-title":"A pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2","volume":"6","author":"Tumban","year":"2011","journal-title":"PLoS ONE"},{"issue":"Jul (34)","key":"10.1016\/j.vaccine.2015.09.005_bib0570","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1016\/j.vaccine.2014.06.054","article-title":"Immunization with a consensus epitope from human papillomavirus L2 induces antibodies that are broadly neutralizing","volume":"32","author":"Tyler","year":"2014","journal-title":"Vaccine"},{"issue":"Jun (26)","key":"10.1016\/j.vaccine.2015.09.005_bib0575","doi-asserted-by":"crossref","first-page":"5516","DOI":"10.1016\/j.vaccine.2006.04.058","article-title":"Protection of rabbits against cutaneous papillomavirus infection using recombinant tobacco mosaic virus containing L2 capsid epitopes","volume":"24","author":"Palmer","year":"2006","journal-title":"Vaccine"},{"issue":"Jun (11)","key":"10.1016\/j.vaccine.2015.09.005_bib0580","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1093\/jnci\/djp106","article-title":"Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines","volume":"101","author":"Jagu","year":"2009","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.vaccine.2015.09.005_bib0585","doi-asserted-by":"crossref","first-page":"e55538","DOI":"10.1371\/journal.pone.0055538","article-title":"Optimization of multimeric human papillomavirus L2 vaccines","volume":"8","author":"Jagu","year":"2013","journal-title":"PLoS ONE"},{"issue":"5","key":"10.1016\/j.vaccine.2015.09.005_bib0590","doi-asserted-by":"crossref","first-page":"e95448","DOI":"10.1371\/journal.pone.0095448","article-title":"A vaccine of L2 epitope repeats fused with a modified IgG1 Fc induced cross-neutralizing antibodies and protective immunity against divergent human papillomavirus types","volume":"9","author":"Chen","year":"2014","journal-title":"PLoS ONE"},{"issue":"Mar (13)","key":"10.1016\/j.vaccine.2015.09.005_bib0595","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/j.vaccine.2009.01.102","article-title":"Potent anti-HPV immune responses induced by tandem repeats of the HPV16 L2 (20\u201338) peptide displayed on bacterial thioredoxin","volume":"27","author":"Rubio","year":"2009","journal-title":"Vaccine"},{"issue":"Feb (7)","key":"10.1016\/j.vaccine.2015.09.005_bib0600","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.vaccine.2008.11.099","article-title":"Vaccination with HPV16 L2E6E7 fusion protein in GPI-0100 adjuvant elicits protective humoral and cell-mediated immunity","volume":"27","author":"Karanam","year":"2009","journal-title":"Vaccine"},{"issue":"May (4)","key":"10.1016\/j.vaccine.2015.09.005_bib0605","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/icb.2009.13","article-title":"Developing vaccines against minor capsid antigen L2 to prevent papillomavirus infection","volume":"87","author":"Karanam","year":"2009","journal-title":"Immunol Cell Biol"},{"issue":"7","key":"10.1016\/j.vaccine.2015.09.005_bib0610","doi-asserted-by":"crossref","first-page":"e101576","DOI":"10.1371\/journal.pone.0101576","article-title":"Measurement of neutralizing serum antibodies of patients vaccinated with human papillomavirus L1 or L2-based immunogens using furin-cleaved HPV Pseudovirions","volume":"9","author":"Wang","year":"2014","journal-title":"PLoS ONE"},{"issue":"Nov (21)","key":"10.1016\/j.vaccine.2015.09.005_bib0615","doi-asserted-by":"crossref","first-page":"11585","DOI":"10.1128\/JVI.01577-07","article-title":"Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2","volume":"81","author":"Gambhira","year":"2007","journal-title":"J Virol"},{"issue":"Dec (24)","key":"10.1016\/j.vaccine.2015.09.005_bib0620","doi-asserted-by":"crossref","first-page":"13253","DOI":"10.1128\/JVI.06093-11","article-title":"A murine genital-challenge model is a sensitive measure of protective antibodies against human papillomavirus infection","volume":"85","author":"Longet","year":"2011","journal-title":"J Virol"},{"issue":"7","key":"10.1016\/j.vaccine.2015.09.005_bib0625","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1128\/CVI.00139-12","article-title":"A human papillomavirus (HPV) in vitro neutralization assay that recapitulates the in vitro process of infection provides a sensitive measure of HPV L2 infection-inhibiting antibodies","volume":"19","author":"Day","year":"2012","journal-title":"Clin Vaccine Immunol"},{"issue":"11","key":"10.1016\/j.vaccine.2015.09.005_bib0630","doi-asserted-by":"crossref","first-page":"e49751","DOI":"10.1371\/journal.pone.0049751","article-title":"VLPs displaying a single L2 epitope induce broadly cross-neutralizing antibodies against human papillomavirus","volume":"7","author":"Tumban","year":"2012","journal-title":"PLoS ONE"},{"issue":"Jan (2)","key":"10.1016\/j.vaccine.2015.09.005_bib0635","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.virol.2010.10.017","article-title":"The N-terminal region of the human papillomavirus L2 protein contains overlapping binding sites for neutralizing, cross-neutralizing and non-neutralizing antibodies","volume":"409","author":"Rubio","year":"2011","journal-title":"Virology"},{"issue":"Feb (3)","key":"10.1016\/j.vaccine.2015.09.005_bib0640","first-page":"E139","article-title":"Natural variants in the major neutralizing epitope of human papillomavirus minor capsid protein L2","volume":"132","author":"Seitz","year":"2013","journal-title":"Int J Cancer"},{"key":"10.1016\/j.vaccine.2015.09.005_bib0645","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1093\/embo-reports\/kve234","article-title":"Electron cryo-microscopy and image reconstruction of adeno-associated virus type 2 empty capsids","volume":"2","author":"Kronenberg","year":"2002","journal-title":"EMBO Rep."},{"key":"10.1016\/j.vaccine.2015.09.005_bib0650","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1038\/71021","article-title":"Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2","volume":"5","author":"Girod","year":"1999","journal-title":"Nat. Med."},{"key":"10.1016\/j.vaccine.2015.09.005_bib0655","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1002\/jgm.1392","article-title":"Engineering adeno-associated virus serotype 2-based targeting vectors using a new insertion site-position 453-and single point mutations","volume":"11","author":"Boucas","year":"2009","journal-title":"J Gene Med"},{"key":"10.1016\/j.vaccine.2015.09.005_bib0660","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1089\/hum.2009.182","article-title":"Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors","volume":"21","author":"Boutin","year":"2010","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.vaccine.2015.09.005_bib0665","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1086\/595830","article-title":"Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses","volume":"199","author":"Calcedo","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2015.09.005_bib0670","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1128\/CVI.05107-11","article-title":"Adeno-associated virus antibody profiles in newborns, children, and adolescents","volume":"18","author":"Calcedo","year":"2011","journal-title":"Clin Vaccine Immunol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15012487?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15012487?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:21:55Z","timestamp":1759400515000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X15012487"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":67,"journal-issue":{"issue":"42","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["S0264410X15012487"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.09.005","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Durable immunity to oncogenic human papillomaviruses elicited by adjuvanted recombinant Adeno-associated virus-like particle immunogen displaying L2 17\u201336 epitopes","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.09.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}